Know Cancer

or
forgot password

Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma


N/A
N/A
N/A
Open (Enrolling)
Both
Lymphoma:, Hodgkin Lymphoma, Non-Hodgkin Lymphoma (Follicular, Diffuse B-cel Lymphoma, PTLD and Mantle Cel Lymphoma)

Thank you

Trial Information

Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma


Inclusion Criteria:



- every patient with a new diagnosis of Hodgkin or Non-Hodgkin Lymphoma (only diffuse
large B-cel lymphoma, mantle cell lymphoma, follicular lymphoma and PTLD)

Exclusion Criteria:

- patient with general contraindications for MRI (pacemaker, claustrophobia, etc.)

- patients with a type of lymphoma other than those described in the inclusion criteria

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

disease stage

Outcome Description:

Lesions are characterized as benign or malignant based on signal intensity and ADC values, enabling correct determination of tumor extent (staging).

Outcome Time Frame:

4 years

Safety Issue:

No

Principal Investigator

vincent vandecaveye, MD PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospitals Leuven

Authority:

Belgium: Federal Agency for Medicinal Products and Health Products

Study ID:

S51160

NCT ID:

NCT01231269

Start Date:

November 2010

Completion Date:

July 2016

Related Keywords:

  • Lymphoma:
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma (Follicular, Diffuse B-cel Lymphoma, PTLD and Mantle Cel Lymphoma)
  • Hodgkin Disease
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location